Inflammation marker and risk of pancreatic cancer: A nested case-control study within the EPIC cohort

V. A. Grote, R. Kaaks, A. Nieters, A. Tjønneland, J. Halkjær, K. Overvad, M. R. Skjelbo Nielsen, M. C. Boutron-Ruault, F. Clavel-Chapelon, A. Racine, B. Teucher, S. Becker, T. Pischon, H. Boeing, A. Trichopoulou, C. Cassapa, V. Stratigakou, D. Palli, V. Krogh, R. TuminoP. Vineis, S. Panico, L. Rodríguez, E. J. Duell, M. J. Sánchez, M. Dorronsoro, C. Navarro, A. B. Gurrea, P. D. Siersema, P. H M Peeters, W. Ye, M. Sund, B. Lindkvist, D. Johansen, K. T. Khaw, N. Wareham, N. E. Allen, R. C. Travis, V. Fedirko, M. Jenab, D. S. Michaud, S. C. Chuang, D. Romaguera, H. B. Bueno-De-Mesquita, S. Rohrmann

Research output: Contribution to journalArticle

Abstract

Background: Established risk factors for pancreatic cancer include smoking, long-standing diabetes, high body fatness, and chronic pancreatitis, all of which can be characterised by aspects of inflammatory processes. However, prospective studies investigating the relation between inflammatory markers and pancreatic cancer risk are scarce. Methods: We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition, measuring prediagnostic blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), and soluble receptors of tumour necrosis factor-α (sTNF-R1, R2) in 455 pancreatic cancer cases and 455 matched controls. Odds ratios (ORs) were estimated using conditional logistic regression models. Results: None of the inflammatory markers were significantly associated with risk of pancreatic cancer overall, although a borderline significant association was observed for higher circulating sTNF-R2 (crude OR=1.52 (95% confidence interval (CI) 0.97-2.39), highest vs lowest quartile). In women, however, higher sTNF-R1 levels were significantly associated with risk of pancreatic cancer (crude OR=1.97 (95% CI 1.02-3.79)). For sTNF-R2, risk associations seemed to be stronger for diabetic individuals and those with a higher BMI. Conclusion: Prospectively, CRP and IL-6 do not seem to have a role in our study with respect to risk of pancreatic cancer, whereas sTNF-R1 seemed to be a risk factor in women and sTNF-R2 might be a mediator in the risk relationship between overweight and diabetes with pancreatic cancer. Further large prospective studies are needed to clarify the role of proinflammatory proteins and cytokines in the pathogenesis of exocrine pancreatic cancer.

Original languageEnglish
Pages (from-to)1866-1874
Number of pages9
JournalBritish Journal of Cancer
Volume106
Issue number11
DOIs
Publication statusPublished - May 22 2012

Keywords

  • CRP
  • EPIC
  • IL-6
  • inflammation
  • pancreatic cancer
  • TNF receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Inflammation marker and risk of pancreatic cancer: A nested case-control study within the EPIC cohort'. Together they form a unique fingerprint.

  • Cite this

    Grote, V. A., Kaaks, R., Nieters, A., Tjønneland, A., Halkjær, J., Overvad, K., Skjelbo Nielsen, M. R., Boutron-Ruault, M. C., Clavel-Chapelon, F., Racine, A., Teucher, B., Becker, S., Pischon, T., Boeing, H., Trichopoulou, A., Cassapa, C., Stratigakou, V., Palli, D., Krogh, V., ... Rohrmann, S. (2012). Inflammation marker and risk of pancreatic cancer: A nested case-control study within the EPIC cohort. British Journal of Cancer, 106(11), 1866-1874. https://doi.org/10.1038/bjc.2012.172